QIAGEN N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.58 USD | -1.02% |
|
-2.11% | -4.90% |
| 05-29 | Qiagen N.V. Launches New Library Preparation Kit, Facilitating Multiomic Studies and Advancing Precision Medicine | CI |
| 05-21 | QIAGEN NV : Berenberg maintains a Buy rating | ZD |
Presenter SpeechSven Björklund;Independent Supervisory Board Chairman (Executives)So ladies an...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Calendar
17/06/2024
- Capital Markets Day
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
42.58
USD
Average target price
50.14
USD
Spread / Average Target
+17.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.90% | 9.54B | |
| +48.67% | 58.71B | |
| -2.76% | 41.31B | |
| +36.42% | 39.2B | |
| -11.22% | 27.4B | |
| +9.25% | 26.55B | |
| -23.10% | 18.98B | |
| +1.88% | 12.51B | |
| +26.43% | 12.08B | |
| +21.74% | 11.94B |
- Stock Market
- Equities
- QGEN Stock
- News Qiagen N.V.
- Transcript : QIAGEN N.V. - Shareholder/Analyst Call
